Beaconcure
Automated Clinical Data Validation for Regulatory Submissions
Company Overview
Snapshot
Founded in January 2016 by Todd Holmes and Ilan Carmeli, Beaconcure operates with 11–50 employees. The company has secured funding across 4 rounds from 3 investors, with NewVale Capital participating as a lead investor. In March 2023, Beaconcure raised a Series B round, demonstrating continued investor confidence in its AI-powered clinical technology platform.
Business overview
Beaconcure develops an automated solution, powered by machine learning and natural language processing, for clinical data validation. Its core product, Verify, is a SaaS system designed to manage clinical trial output data and automate the validation of statistical analysis for regulatory submissions. The company serves the pharmaceutical industry, including pharma companies and healthcare providers, by improving the quality assurance of clinical trials and accelerating the drug and vaccine development process.
Strategic signal
In August 2023, Beaconcure announced it had raised a total of $20 million in equity and an additional $650,000 grant, alongside securing five major clients including Pfizer and Ono Pharmaceutical This signals strong market validation and significant growth potential, indicating that the company's automated clinical data validation solution is gaining traction with leading pharmaceutical companies and is poised for further expansion in the drug and vaccine development sector.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant funding event for Beaconcure?
- In March 2023, Beaconcure raised a Series B funding round with participation from NewVale Capital, aimed at expanding its AI-powered clinical technology platform.
- What was a key strategic move for Beaconcure in 2022?
- In April 2022, Beaconcure announced plans for US expansion, including relocating its CEO to Boston, to improve commercial coverage and address the need for digitization in clinical trials.
- How has Beaconcure collaborated with Pfizer?
- Beaconcure partnered with Pfizer to validate data from their COVID-19 vaccine clinical trials, demonstrating the effectiveness of its Verify platform in identifying inconsistencies and errors in clinical trial datasets.
- What was a notable early investment in Beaconcure?
- In March 2018, Beaconcure secured a Seed funding round, with Random Forest VC participating as a lead investor.
- What grant did Beaconcure receive in 2018?
- In January 2018, Beaconcure received a grant from the Israel Innovation Authority.